ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2530

Clinical Specialty Setting As a Determinant for Disease Management in Patients with Psoriatic Arthritis: An Interim Analysis of the Cross-Sectional Observational Study

Wolf-Henning Boehncke1, Rudolf Horváth2, Ediz Dalkiliç3, Sȏnia A L Lima4, Masato Okada5, Maja Hojnik6, Fabiana Ganz7 and Ennio Lubrano8, 1Geneva University Hospital and University of Geneva, Geneva, Switzerland, 2Department of Pediatric and Adult Rheumatology, University Hospital Motol, Prague, Czech Republic, 3Department of Internal Medicine, Division of Rheumatology, Uludag University School of Medicine, Gorukle, Bursa, Turkey, 4ABC Medical School, Santo André, Brazil, 5Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 6AbbVie, Ljubljana, Slovenia, 7AbbVie AG, Baar, Switzerland, 8Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Clinical practice, management and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Evidence suggests that timely and effective management can improve long-term outcomes in patients (pts) with psoriatic arthritis (PsA); however factors influencing treatment management decisions are not well understood. The objective of this study is to evaluate the association between the clinical specialty setting and time from inflammatory musculoskeletal symptom onset to PsA diagnosis and to different management steps in pts with a diagnosis of PsA.

 

Methods: LOOP is a large cross-sectional, multi-center observational study currently being conducted in 19 countries across Western and Eastern Europe, Latin America, and Asia. Adult pts (≥18 years) with a suspected or an established diagnosis of PsA who are routinely visiting a rheumatologist (rheum), dermatologist (derm) or non-rheum/non-derm site are eligible to participate in this study. Each enrolled patient is being assessed by both rheum and derm in the study. The present interim analysis included pts enrolled by 23 May 2017, which corresponded to approximately 50% of the total protocol specified sample size.

Results: Of the 602 pts enrolled by database cut-off date, 518 pts with a confirmed diagnosis of PsA were included in this interim analysis. A majority of pts were recruited by rheums (308, 59.5%), followed by derms (210, 40.5%) and physiatrists (19, 3.7%). PsA was first diagnosed by a rheum in 372 (71.8%) pts and by a derm in 100 pts (19.3%). Baseline demographics and disease characteristics were mostly comparable between PsA pts in rheum and derm settings (Table 1). The timing of different disease management steps by clinical specialty is reported in Table 2. The mean time from symptom onset to PsA diagnosis was 23 months (mo) in the rheum setting and 2 mo longer for derms. The mean time from PsA diagnosis to first conventional synthetic DMARD (csDMARD) and first biologic DMARD (bDMARD) for rheums were 9 and 53 mo, respectively. Compared with Rheums, Derms required additional 16 and 14 mo to prescribe first csDMARD (P = 0.015 vs Rheum) and first bDMARD, respectively. The mean time from first csDMARD to first bDMARD was 46 mo for rheum; while it was 6 months shorter for derm.

Conclusion: Although the duration from musculoskeletal symptom onset to PsA diagnosis was similar between rheum and derm setting, there were differences in the timing of introduction of different DMARD classes. Notably, mean time to first csDMARD was significantly and mean time to first bDMARD numerically shorter in rheum setting. The data lend further support to the need for rheum-derm collaborative approach to optimize management of pts with PsA.


Disclosure: W. H. Boehncke, Abbvie, Biogen Idec, Celgene, Covagen, Galderma, Janssen, Leo, Lilly, MSD, Novartis, Pantec Biosolutions, Pfizer, and UCB, 2,Abbvie, Biogen Idec, Celgene, Covagen, Galderma, Janssen, Leo, Lilly, MSD, Novartis, Pantec Biosolutions, Pfizer, and UCB, 5,Abbvie, Biogen Idec, Celgene, Covagen, Galderma, Janssen, Leo, Lilly, MSD, Novartis, Pantec Biosolutions, Pfizer, and UCB, 9; R. Horváth, AbbVie, MSD, Novartis, Pfizer, and UCB, 2,AbbVie, MSD, Novartis, Pfizer, and UCB, 5,AbbVie, MSD, Novartis, Pfizer, and UCB, 9; E. Dalkiliç, AbbVie, 2,AbbVie, MSD, Pfizer, Roche, and UCBizer, 8; S. A. L. Lima, Abbive, BMS, and Janssen, 5,Abbive, BMS, and Janssen, 9; M. Okada, AbbVie Japan, Ayumi Pharmaceutical, Eli Lilly and Company, Mitsubishi Tanabe Pharma, and Ono Pharmaceutical, 2,AbbVie Japan, Ayumi Pharmaceutical, Eli Lilly and Company, Mitsubishi Tanabe Pharma, and Ono Pharmaceutical, 5,AbbVie Japan, Ayumi Pharmaceutical, Eli Lilly and Company, Mitsubishi Tanabe Pharma, and Ono Pharmaceutical, 9; M. Hojnik, Abbvie, 1,abbvie, 3; F. Ganz, Abbvie, 1,AbbVie, 3; E. Lubrano, AbbVie, Celgene, Janssen, MSD, Novartis, and Pfizer, 2,AbbVie, Celgene, Janssen, MSD, Novartis, and Pfizer, 5,AbbVie, Celgene, Janssen, MSD, Novartis, and Pfizer, 9.

To cite this abstract in AMA style:

Boehncke WH, Horváth R, Dalkiliç E, Lima SAL, Okada M, Hojnik M, Ganz F, Lubrano E. Clinical Specialty Setting As a Determinant for Disease Management in Patients with Psoriatic Arthritis: An Interim Analysis of the Cross-Sectional Observational Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/clinical-specialty-setting-as-a-determinant-for-disease-management-in-patients-with-psoriatic-arthritis-an-interim-analysis-of-the-cross-sectional-observational-study/. Accessed September 24, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-specialty-setting-as-a-determinant-for-disease-management-in-patients-with-psoriatic-arthritis-an-interim-analysis-of-the-cross-sectional-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology